GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Cash And Cash Equivalents

Sumitomo Pharma Co (Sumitomo Pharma Co) Cash And Cash Equivalents : $253 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Cash And Cash Equivalents?

Sumitomo Pharma Co's quarterly cash and cash equivalents declined from Jun. 2023 ($668.34 Mil) to Sep. 2023 ($408.52 Mil) but then stayed the same from Sep. 2023 ($408.52 Mil) to Dec. 2023 ($253.21 Mil).

Sumitomo Pharma Co's annual cash and cash equivalents declined from Mar. 2021 ($1,781.97 Mil) to Mar. 2022 ($1,711.83 Mil) and declined from Mar. 2022 ($1,711.83 Mil) to Mar. 2023 ($1,073.42 Mil).

Sumitomo Pharma Co Cash And Cash Equivalents Historical Data

The historical data trend for Sumitomo Pharma Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Cash And Cash Equivalents Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,235.30 944.65 1,781.97 1,711.83 1,073.42

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,969.93 1,073.42 668.34 408.52 253.21

Sumitomo Pharma Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sumitomo Pharma Co  (OTCPK:DNPUF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sumitomo Pharma Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Cash And Cash Equivalents
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.